Pharmaceutical - Xofigo, Regulation, Oncology


Current filters:


Germany’s IQWiG views Xofigo, Kadcyla and Eviplera


In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo


The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

EU approval for Bayer’s prostate cancer drug Xofigo

EU approval for Bayer’s prostate cancer drug Xofigo


The European Commission has granted marketing authorization for German drug and chemical major Bayer’s…


EMA unit backs approval of Bayer's radium-233

EMA unit backs approval of Bayer's radium-233


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

AlgetaBayerEuropeOncologyPharmaceuticalradium-223 dichlorideRegulationXofigo

Fast FDA approval for Bayer's new drug for advanced prostate cancer, Xofigo


The US Food and Drug Administration yesterday (May 15) approved Xofigo (radium Ra 223 dichloride, initially…

AlgetaAstellas PharmaBayerNorth AmericaOncologyPharmaceuticalRegulationXofigo

Back to top